• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氟尿烷树脂涂层薄膜用于预防和处理镥-奥曲肽表面污染的临床评估。

Clinical evaluation of fluorine-urethane resin-coated films for preventing and managing Lu-DOTATATE surface contamination.

作者信息

Okuhata Katsuya, Monzen Hajime, Takai Go, Hosono Makoto

机构信息

Department of Radiology, Kansai Electric Power Hospital, 2-1-7 Fukushima, Fukushima-ku, Osaka-shi, Osaka, 5530003, Japan.

Department of Medical Physics, Graduate School of Medical Sciences, Kindai University, 377-2 Onohigashi, Osakasayama-shi, Osaka, 5898511, Japan.

出版信息

Ann Nucl Med. 2025 Jun 23. doi: 10.1007/s12149-025-02064-1.

DOI:10.1007/s12149-025-02064-1
PMID:40549103
Abstract

OBJECTIVE

Lu-DOTATATE and Lu-PSMA-617 used as therapeutic radiopharmaceuticals are primarily excreted in urine and may cause relatively high levels of contamination in toilets and sink areas. This study aimed to comprehensively evaluate a novel fluorine-coated film as a practical solution for the management of Lu-DOTATATE contamination by (1) quantifying its decontamination efficiency, (2) assessing its effectiveness in clinical settings, and (3) identifying optimal applications in nuclear medicine facilities.

METHODS

The developed hydrophobic films [fluorine-coated film (F-film) and fluorine-urethane resin-coated film (FU-film)] were prepared along with a commercial hydrophobic film (Aquaglide), stainless-steel plate, sink, and urine bag were used as the test materials. Contact angles were measured using the sessile-drop method. The relationship between the contact angle of each test material (excluding the sink) and the count reduction rate after applying Lu-DOTATATE (4.93 Bq/ml, 0.1 ml) was investigated. Each measurement was performed three times. To confirm the effectiveness in a clinical setting, the FU-film was applied to a toilet bowl, and the contamination after urination by patients who were administered Lu-DOTATATE was evaluated.

RESULTS

A strong positive correlation (r = 0.84, p = 0.001) was observed between the contact angle of the test material surface and the reduction rate of the count after wiping with a wet paper towel. Specifically, the counts of the F-film, FU-film, and Aquaglide, which had contact angles greater than 90°, decreased by 92.1%, 96.8%, and 97.4%, respectively, and the counts on the sink and the stainless-steel plate decreased by 71.9% and 69.2%, respectively. The count of the FU-film was 23.3% lower than that of the urine bag. The density of surface contamination of the FU-film after flushing was 62.2% lower than that of the toilet bowl and was lower than the background level.

CONCLUSION

The developed FU-film effectively prevents and reduces Lu-DOTATATE contamination, with a reduction rate as high as 96.8%. This is particularly useful for protecting areas where water flows directly, such as sinks and toilet bowls, and also for protecting other medical materials that may be contaminated with urine.

摘要

目的

作为治疗性放射性药物的镥-奥曲肽和镥-PSMA-617主要经尿液排泄,可能会在马桶和水槽区域造成较高程度的污染。本研究旨在全面评估一种新型氟涂层薄膜,作为管理镥-奥曲肽污染的实用解决方案,具体包括:(1)量化其去污效率;(2)评估其在临床环境中的有效性;(3)确定在核医学设施中的最佳应用。

方法

制备了所开发的疏水薄膜[氟涂层薄膜(F薄膜)和氟聚氨酯树脂涂层薄膜(FU薄膜)],并使用一种商用疏水薄膜(Aquaglide)、不锈钢板、水槽和尿袋作为测试材料。采用静滴法测量接触角。研究了每种测试材料(不包括水槽)的接触角与涂抹镥-奥曲肽(4.93 Bq/ml,0.1 ml)后计数减少率之间的关系。每次测量重复进行三次。为确认在临床环境中的有效性,将FU薄膜应用于马桶,评估接受镥-奥曲肽治疗的患者排尿后的污染情况。

结果

测试材料表面的接触角与用湿纸巾擦拭后计数的减少率之间观察到强正相关(r = 0.84,p = 0.001)。具体而言,接触角大于90°的F薄膜、FU薄膜和Aquaglide的计数分别减少了92.1%、96.8%和97.4%,水槽和不锈钢板上的计数分别减少了71.9%和69.2%。FU薄膜的计数比尿袋低23.3%。冲洗后FU薄膜的表面污染密度比马桶低62.2%,且低于背景水平。

结论

所开发的FU薄膜能有效预防和减少镥-奥曲肽污染,减少率高达96.8%。这对于保护水槽和马桶等水直接流动的区域,以及保护其他可能被尿液污染的医疗材料特别有用。

相似文献

1
Clinical evaluation of fluorine-urethane resin-coated films for preventing and managing Lu-DOTATATE surface contamination.氟尿烷树脂涂层薄膜用于预防和处理镥-奥曲肽表面污染的临床评估。
Ann Nucl Med. 2025 Jun 23. doi: 10.1007/s12149-025-02064-1.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Multicycle Dosimetric Behavior and Dose-Effect Relationships in [Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy.[镥]镥-奥曲肽肽受体放射性核素治疗中的多周期剂量学行为及剂量效应关系
J Nucl Med. 2025 Jun 2;66(6):900-908. doi: 10.2967/jnumed.124.269389.
4
Dosimetry of [Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.晚期中肠神经内分泌肿瘤患者中[镥]镥-奥曲肽的剂量测定:III期NETTER-1试验子研究结果
J Nucl Med. 2025 Mar 3;66(3):449-456. doi: 10.2967/jnumed.124.268903.
5
Can Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data.能否通过治疗前的生长抑素受体(SSTR)正电子发射断层扫描(PET)预测镥-奥曲肽(Lu-DOTATATE)在肾脏的吸收剂量?多中心数据研究结果
J Nucl Med. 2025 Jul 1;66(7):1082-1090. doi: 10.2967/jnumed.124.269098.
6
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.静脉注射硫酸镁和索他洛尔预防冠状动脉搭桥术后房颤:系统评价与经济学评估
Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. doi: 10.3310/hta12280.
7
Is Your Surgical Helmet System Compromising the Sterile Field? A Systematic Review of Contamination Risks and Preventive Measures in Total Joint Arthroplasty.您的手术头盔系统是否会破坏无菌区域?全关节置换术中污染风险与预防措施的系统评价。
Clin Orthop Relat Res. 2025 Feb 5. doi: 10.1097/CORR.0000000000003383.
8
Extravasation Frequency of [Lu]Lu-DOTATATE: Insights and Implications Derived from 1,314 Cycles of Treated Patients-A Single-Site Analysis.[镥]镥-奥曲肽的外渗频率:来自1314例治疗患者周期的见解与启示——单中心分析
J Nucl Med. 2025 Aug 1;66(8):1258-1264. doi: 10.2967/jnumed.124.269411.
9
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
10
Cost-Effectiveness of [Lu]Lu-DOTATATE for the Treatment of Newly Diagnosed Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Analysis Based on Results of the NETTER-2 Trial.[镥]镥-奥曲肽治疗新诊断的晚期胃肠胰神经内分泌肿瘤的成本效益:基于NETTER-2试验结果的分析
J Nucl Med. 2025 Jul 1;66(7):1075-1081. doi: 10.2967/jnumed.124.269416.

本文引用的文献

1
Ion solvation as a predictor of lanthanide adsorption structures and energetics in alumina nanopores.离子溶剂化作为氧化铝纳米孔中镧系元素吸附结构和能量学的预测指标。
Commun Chem. 2023 Aug 22;6(1):172. doi: 10.1038/s42004-023-00978-3.
2
Effectiveness of shielding materials against Lu gamma rays and the corresponding distance relationship.屏蔽材料对镥γ射线的屏蔽效果及相应的距离关系。
Ann Nucl Med. 2023 Nov;37(11):629-634. doi: 10.1007/s12149-023-01860-x. Epub 2023 Aug 19.
3
A proof of principle study using radiopharmaceuticals to quantify and localize container-content interactions in medical syringes.
使用放射性药物定量和定位医用注射器中容器内容物相互作用的原理研究证明。
Sci Rep. 2023 Feb 15;13(1):2721. doi: 10.1038/s41598-023-29923-z.
4
Manual on the proper use of meta-[At] astato-benzylguanidine ([At] MABG) injections in clinical trials for targeted alpha therapy (1st edition).用于靶向 α 治疗临床试验中注射用 meta-[At] 间位碘代苄胍(MABG)的正确使用手册(第一版)。
Ann Nucl Med. 2022 Aug;36(8):695-709. doi: 10.1007/s12149-022-01765-1. Epub 2022 Jul 6.
5
PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties.PSMA-D4 放射性配体靶向治疗前列腺癌:合成、特性和生物学特性初步评估。
Int J Mol Sci. 2021 Mar 8;22(5):2731. doi: 10.3390/ijms22052731.
6
External radiation exposure, excretion, and effective half-life in Lu-PSMA-targeted therapies.镥-PSMA靶向治疗中的外照射暴露、排泄及有效半衰期。
EJNMMI Res. 2018 Apr 12;8(1):32. doi: 10.1186/s13550-018-0386-4.
7
Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.).镥[177Lu]标记生长抑素类似物(Lu-177-DOTA-TATE)注射液在放射性核素治疗中的正确使用手册(第 2 版)。
Ann Nucl Med. 2018 Apr;32(3):217-235. doi: 10.1007/s12149-018-1230-7. Epub 2018 Jan 15.
8
Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?[(177)Lu-DOTA(0),Tyr(3)]奥曲肽与[(177)Lu-DOTA(0),Tyr(3)]奥曲肽的比较:哪种肽更适合肽受体放射性核素治疗?
Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1346-51. doi: 10.1007/s00259-006-0172-9. Epub 2006 Jul 18.